Human CTH adenoviral particles

The CTH gene encodes cystathionine gamma-lyase (CSE), which plays a vital role in the transsulfurization pathway, a key metabolic process for the production of hydrogen sulfide (H₂S). H₂S is an important gaseous signaling molecule involved in a variety of physiological functions, including vasodilation, anti-inflammatory responses, and cytoprotection. The CTH gene is expressed in a variety of tissues, especially in the liver, kidneys, and cardiovascular system, where it helps maintain redox balance and regulates cellular stress responses. Dysregulation of CTH expression or activity has been associated with a variety of pathological conditions, such as cardiovascular disease, neurodegenerative diseases, and diabetes. Given its therapeutic potential, the CTH gene has become a target for genetic and pharmacological interventions aimed at restoring H₂S homeostasis in disease states.

Human CTH adenoviral particles are genetically engineered viral vectors designed to deliver the CTH gene to target cells for research or therapeutic purposes. These particles are derived from replication-defective adenoviruses, ensuring efficient gene transduction while minimizing the risk of viral replication. This adenoviral vector system has high transduction efficiency, broad tropism, and the ability to infect both dividing and non-dividing cells, making it an ideal tool for gene delivery. Human CTH adenoviral particles enable researchers to overexpress the CTH gene in vitro or in vivo, thereby facilitating the study of hydrogen sulfide (H2S) signaling pathways, disease mechanisms, and potential therapeutic strategies. In addition, these vectors also have great prospects for gene therapy applications, especially in diseases associated with CTH deficiency or impaired H2S production. Preclinical studies have shown that they have the potential to improve endothelial dysfunction, reduce oxidative stress, and promote tissue repair.